B12 wins when deficiency explains the fatigue. MOTS-c wins the mitochondrial-research question. NAD+ wins when the goal is a direct NAD routine. Glutathione occupies the antioxidant lane. Start with the cause, then choose the molecule.
Comparison at a glance
| Option | Best reason to consider it | Routine | Most relevant evidence | Verdict |
|---|---|---|---|---|
| MOTS-c injection | Mitochondrial and metabolic research interest | Product guide covers concentration, schedule, supply, storage, and price | Human endogenous exercise data plus administered mouse studies; Phase 2 recruiting | Best research match |
| NAD+ formats | A direct NAD+ routine | Injection, nasal spray, and sublingual tablet available | Cellular coenzyme biology; felt-energy results uncertain | Best current choice for NAD+ intent |
| Methylcobalamin B12 injection | Testing shows low B12 | 5 mg/mL, 10 mL, 60 days, $44.50 first month, then $89/month | Deficiency treatment | Best cause-to-treatment answer when B12 is low |
| Glutathione injection | Antioxidant intent | Current 30-day injection, $74.50 first month, then $149/month | Antioxidant biology | Best match for antioxidant intent |
B12 wins when deficiency is the cause. MOTS-c is the mitochondrial-research leader but is not available. NAD+ is the current direct-coenzyme choice; glutathione belongs to antioxidant intent.
The decisive distinction
B12, MOTS-c, NAD+, and glutathione have four different jobs: deficiency correction, mitochondrial signaling research, direct coenzyme use, and antioxidant intent.
What MOTS-c is
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA and detected in human skeletal muscle and circulation. Rebody's intended MOTS-c format is an injection vial. This identity keeps similar names, salts, precursors, endogenous physiology, and finished products from being compared as though they were one molecule.
Keep every result attached to its molecule, route, and model. That preserves the useful distinction among exercise-responsive MOTS-c, direct NAD+ formats, B12 deficiency treatment, and glutathione antioxidant biology.
What the strongest evidence measured
In 10 young men, a stationary-bike session increased the body's own MOTS-c in skeletal muscle and serum. Administered MOTS-c improved physical-capacity or metabolic measures in mice. A recruiting Phase 2a trial plans 120 adults with prediabetes and overweight or obesity, 12 weeks of subcutaneous MOTS-c or placebo, and an OGTT-derived insulin-sensitivity endpoint.
For MOTS-c, NAD+, B12, and glutathione, the molecule, route, study population, duration, and measured endpoint define the claim. Route, storage, schedule, supply, and price decide whether the best-matched option is practical.
Four “energy” products, four different jobs
MOTS-c is a mitochondrial-encoded signaling peptide. Its human research shows that exercise changes endogenous MOTS-c, while administered metabolic and capacity findings come from mice. NAD+ is a coenzyme category with current injection, nasal, and sublingual options. B12 is a vitamin whose deficiency can directly explain fatigue and cognitive symptoms. Glutathione belongs to antioxidant and redox interest.
The word energy hides those differences. A low B12 result gives B12 the strongest causal case. A shopper specifically interested in NAD biology has three current NAD+ formats to compare. MOTS-c is the research-forward choice for mitochondrial signaling and insulin-sensitivity questions. Glutathione should not be promoted to an endurance treatment merely because oxidative stress appears in exercise science.
Track the outcome that belongs to the chosen lane. B12 has laboratory context; metabolic MOTS-c interest points toward glucose measures and repeatable capacity; NAD+ interest needs a defined functional goal; glutathione questions should remain tied to its actual formulation and purpose.
Price should be normalized to days of supply and route burden. A 60-day injection package cannot be compared with a 30-day spray by sticker price alone. Supplies, cold handling, daily technique, and refill frequency all belong in the ownership cost.
The cause screen remains more important than the product shelf. Persistent fatigue can reflect inadequate sleep, iron deficiency, thyroid disease, medication effects, under-fueling, infection, depression, cardiovascular disease, or low B12. MOTS-c is not an umbrella answer for that list. A measured B12 problem should move directly to the B12 lane; a metabolic research question can keep MOTS-c at the front.
MOTS-c owns the metabolic-research question
B12 wins for deficiency, MOTS-c for mitochondrial research, and NAD+ for a direct NAD routine. The recommendation follows the exact molecule, route, model or population, duration, and endpoint rather than a shared peptide label.
MOTS-c is the mitochondrial-research choice, B12 is the deficiency choice, NAD+ is the direct-coenzyme routine, and glutathione is the antioxidant choice. Each needs its own evidence and outcome.
Use the cause as the tiebreaker
Choose B12 when a measured deficiency explains the complaint. Choose NAD+ when the customer explicitly wants a direct coenzyme routine and has decided among injection, nasal spray, and sublingual tablets. Choose glutathione for antioxidant intent. Choose MOTS-c research when the question is mitochondrial signaling or insulin sensitivity; its guide keeps administered-human results and product facts separate.
This is a hierarchy, not a stack. Combining all four destroys attribution and raises cost without creating evidence that the mixture improves energy.
The same hierarchy improves tracking. B12 can follow the deficient marker and linked symptoms. NAD+ needs a defined daily function such as the afternoon crash or a repeatable focus block. MOTS-c research points toward glucose regulation and metabolic capacity. Glutathione stays tied to antioxidant intent. One product, one reason, and one outcome makes the result readable.
Route and price are separate from mechanism
NAD+ injection is $223.50 for the first two-month shipment, then $298 every two months ($149/month equivalent); the current Rebody 12 mL nasal spray is $59.50 first month, then $119/month; sublingual tablets are $99.50 first month, then $199/month. B12 injection is $44.50 first month, then $89/month. Glutathione injection is $74.50 first month, then $149/month.
Those prices describe current products, not equivalence. An injection adds clean preparation, supplies, site rotation, storage, and sharps. A spray adds priming, nasal comfort, and pump care. A sublingual tablet adds a consistent dissolve step.
MOTS-c has no final public chemical form, concentration, vial, schedule, supply, storage, or price. A research-market vial cannot fill those blanks.
The claim each product earns
MOTS-c earns the mitochondrial-signaling and insulin-sensitivity research claim. NAD+ earns the direct-coenzyme claim. B12 earns the clearest cause-to-treatment claim when deficiency is measured. Glutathione earns the antioxidant claim. Each product becomes easier to judge when the endpoint matches that job.
The wrong winner usually starts with the wrong test
Do not use a generic “energy” score to choose among these products. For suspected B12 deficiency, the decision begins with symptoms, dietary and medication history, and appropriate laboratory evaluation. For NAD+ interest, decide whether the goal is simply a direct coenzyme routine and whether injection, the current 12 mL nasal spray, or sublingual tablets is realistic. For MOTS-c, the relevant human question remains metabolic signaling and the pending administered-human trial—not whether one afternoon felt more productive.
Set one outcome before starting anything: correction of a documented deficiency, a repeatable fatigue measure, or a defined metabolic endpoint. Changing several products, caffeine intake, sleep, and training at once makes the “winner” impossible to identify. Mechanism chooses the lane; a stable observation decides whether the choice helped.
Questions about MOTS-c, NAD+, and B12
Which one is best for fatigue?
B12 is the clearest answer when deficiency is present. Otherwise, fatigue needs a cause: sleep, anemia, thyroid, medication, mood, infection, under-fueling, cardiovascular capacity, or glucose regulation can point elsewhere.
Is MOTS-c stronger than NAD+?
MOTS-c is a signaling peptide; NAD+ is a coenzyme. The useful comparison is mitochondrial research versus a direct NAD routine, followed by the outcome attached to each.
Can NAD+ replace B12?
A documented B12 deficiency calls for B12. NAD+ remains a separate direct-coenzyme routine.
Can MOTS-c and NAD+ be used together?
A plausible mechanism is not a combination trial. Starting both together prevents clean attribution and should not be inferred from separate research.
Which option is allowed in tested sport?
MOTS-c is prohibited under the 2026 WADA list. The antidoping status of other products must be checked separately; one substance’s status does not transfer across the group.
What to track for each winner
For B12, track the deficiency marker and the symptoms tied to it. For NAD+, use a defined function or energy outcome while keeping sleep, caffeine, meals, and training stable. For glutathione, do not convert an antioxidant mechanism into a performance endpoint. For future MOTS-c use, the most relevant human trial question is insulin sensitivity, not a first-day feeling.
Safety is route-specific
Injection products can cause pain, redness, swelling, bruising, or infection. Nasal products can cause burning, congestion, irritation, unpleasant taste, or nosebleeds. Serious swelling, breathing difficulty, fainting, severe chest pain, major neurologic symptoms, or serious-infection signs require urgent help.
MOTS-c’s broader administered-human safety record is one reason the Phase 2a trial is collecting adverse events, laboratory data, vital signs, and ECG information.
Decisive bottom line
B12 wins a deficiency case. NAD+ wins direct coenzyme interest. Glutathione wins antioxidant intent. MOTS-c wins the mitochondrial-research question and remains WADA-prohibited while its administered-human trial proceeds. Four products, four jobs, one clear starting point: identify the cause of the energy problem.
Keep reading
- Cellular-Energy Injections: MOTS-C, NAD+, B12, and Glutathione
- Mitochondrial Health Peptides for Healthy Aging
- Mitochondrial Peptides and Cellular-Energy Treatments